[{"address1": "4710 Bellaire Boulevard", "address2": "Suite 210", "city": "Bellaire", "state": "TX", "zip": "77401", "country": "United States", "phone": "832 742 1357", "website": "https://www.biopathholdings.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.", "fullTimeEmployees": 10, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas P. Morris", "age": 68, "title": "Co-Founder, Chairman, Director of Investor Relations & Secretary", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 76731, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Hickey M.B.A.", "title": "VP of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Price MBA", "title": "Senior Vice President of Finance, Accounting & Administration", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ana Tari Ashizawa M.B.A., MBA, Ph.D.", "title": "Senior Vice President of Research, Development & Clinical Design", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.07, "open": 0.0712, "dayLow": 0.0611, "dayHigh": 0.0712, "regularMarketPreviousClose": 0.07, "regularMarketOpen": 0.0712, "regularMarketDayLow": 0.0611, "regularMarketDayHigh": 0.0712, "payoutRatio": 0.0, "beta": -0.083, "forwardPE": -0.014851485, "volume": 358, "regularMarketVolume": 358, "averageVolume": 70492, "averageVolume10days": 66900, "averageDailyVolume10Day": 66900, "bid": 0.0611, "ask": 0.071, "bidSize": 69775, "askSize": 30000, "marketCap": 498473, "fiftyTwoWeekLow": 0.05, "fiftyTwoWeekHigh": 3.39, "allTimeHigh": 24000.0, "allTimeLow": 0.05, "fiftyDayAverage": 0.1054, "twoHundredDayAverage": 0.3055, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "floatShares": 7956053, "sharesOutstanding": 8307892, "sharesShort": 79346, "sharesShortPriorMonth": 249950, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0138, "heldPercentInsiders": 0.0002, "heldPercentInstitutions": 0.05252, "shortRatio": 0.43, "shortPercentOfFloat": 0.0138, "impliedSharesOutstanding": 8307893, "bookValue": -0.862, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -12317000, "trailingEps": -0.64, "forwardEps": -4.04, "lastSplitFactor": "1:20", "lastSplitDate": 1708646400, "52WeekChange": -0.92941177, "SandP52WeekChange": 0.17904854, "quoteType": "EQUITY", "currentPrice": 0.06, "recommendationKey": "none", "ebitda": -13023000, "totalDebt": 479000, "currentRatio": 0.086, "returnOnAssets": -2.78436, "freeCashflow": -2841750, "operatingCashflow": -7905000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "BPTH", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "corporateActions": [], "regularMarketTime": 1759449600, "exchange": "PNK", "messageBoardId": "finmb_37512626", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "shortName": "Bio-Path Holdings, Inc.", "longName": "Bio-Path Holdings, Inc.", "regularMarketChangePercent": -14.285716, "regularMarketPrice": 0.06, "averageDailyVolume3Month": 70492, "fiftyTwoWeekLowChange": 0.009999998, "fiftyTwoWeekLowChangePercent": 0.19999996, "fiftyTwoWeekRange": "0.05 - 3.39", "fiftyTwoWeekHighChange": -3.3300002, "fiftyTwoWeekHighChangePercent": -0.9823009, "fiftyTwoWeekChangePercent": -92.94118, "dividendDate": 1547769600, "earningsTimestampStart": 1763064000, "earningsTimestampEnd": 1763064000, "earningsCallTimestampStart": 1731677400, "earningsCallTimestampEnd": 1731677400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.64, "epsForward": -4.04, "fiftyDayAverageChange": -0.045400005, "fiftyDayAverageChangePercent": -0.43074006, "twoHundredDayAverageChange": -0.2455, "twoHundredDayAverageChangePercent": -0.80360067, "priceToBook": -0.06960557, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1204641000000, "regularMarketChange": -0.010000002, "regularMarketDayRange": "0.0611 - 0.0712", "fullExchangeName": "OTC Markets OTCPK", "displayName": "Bio-Path", "trailingPegRatio": null, "__fetch_time": "2025-10-04"}]